Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 36Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 11Neoplasms 9Neoplasm Metastasis 9Sarcoma 4Lung Neoplasms 4Esophageal Neoplasms 4Adenocarcinoma 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Melanoma 3Breast Neoplasms, Male 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Diseases 2Metastatic Pancreatic Adenocarcinoma 2Carcinoma 2Advanced Solid Tumor 2Tongue Neoplasms 1Thymus Neoplasms 1Solid Cancer 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic cancer, adult 1Ovarian Neoplasms 1

Interventions

apatinib 1Cyclophosphamide 1Albumin-Bound Paclitaxel 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Triple Negative Breast Cancer × Albumin-Bound Paclitaxel × Clear all
NCT05019690 2024-09-19

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Fujian Cancer Hospital

Phase 1/2 Recruiting
29 enrolled
Breast

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡